Fig. 1 | npj Primary Care Respiratory Medicine

Fig. 1

From: Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials

Fig. 1

Clinically important deteriorations (CID): glycopyrronium versus tiotropium subgroup analysis. Forest plot depicting the results of a subgroup analysis which assessed the risk of experiencing a clinically important deterioration with glycopyrronium (GLY; n = 1859) treatment compared with tiotropium (TIO; n = 1077), based on gender, age, smoking status, exacerbation history, inhaled corticosteroid (ICS) use, baseline St. George’s Respiratory Questionnaire (SGRQ), Baseline Dyspnea Index (BDI) score, COPD severity or blood eosinophil levels. Hazard ratios ±95% confidence intervals (CI) are shown

Back to article page